Naloxegol to Prevent Lower Gastrointestinal Paralysis in Critically Ill Adults Administered Opioids

Phase 4

Terminated

Conditions: Constipation

Interventions: Drug: Placebo Oral Tablet
Drug: Naloxegol Oral Tablet
Drug: Docusate Sodium 100 Mg oral capsule [Colace]
Drug: Senna 217 Mg Oral Tablet
Drug: Polyethylene Glycols
Drug: Bisacodyl 10 mg Suppository
Drug: Magnesium Citrate Oral Liquid Product
Drug: Methylnaltrexone

Registration Number: NCT02977286

Lead Sponsor: Tufts Medical Center

Brief Summary: This study evaluates the addition of naloxegol (Movantik) to a laxative protocol in critically ill adults requiring scheduled opioid (e.g. fentanyl) therapy. Half of the participants will receive naloxegol and a laxative protocol and half the participants will receive a placebo and a laxative protocol.

Detailed Description: Among the more than 5 million adults who are admitted to the ICU each year in the USA, most have pain and thus receive a pain (analgesic) medication called an opioid. Opioid use in critically ill adults continues to increase given the greater awareness of untreated pain in the ICU and that an opioid-first approach be used to optimize patient safety and comfort and improve tolerance with breathing machines (i.e. mechanical ventilation). Similar to constipation, paralysis of the lower gastrointestinal (GI) tract is defined as the inability to pass stool due to impaired gut movement, and is a common effect of opioid use in the critically ill. Lower GI tract paralysis may lead to nausea, vomiting, aspiration, compromise the ability to administer tube feeds (enteral nutrition), an increase abdominal pain, delirium and delay getting off mechanical ventilation. One recent randomized study found that aggressive use of laxatives to prevent lower GI tract paralysis in critically ill adults was associated with lower daily organ dysfunction \[as measured by the Sequential Organ Failure Assessment (SOFA) score\]. The lower GI tract paralysis that occurs in the critically ill often responds poorly to laxative medication therapy (e.g., senna, bisacodyl, lactulose). While stool softener medications like docusate are routinely administered to patients on opioids, laxative-based protocols are frequently not initiated in the ICU until signs of lower GI tract paralysis start to appear. There is therefore an important and unmet need for a safe and efficacious medication to prevent lower GI tract paralysis in critically ill adults who are initiated on opioid therapy. Naloxegol (Movantik) is a naloxone-like drug that blocks the effect of opioids on the opioid µ receptor in the gut but is not absorbed in the brain (and therefore does not block the pain effects of opioids). Naloxegol is currently approved by the Food and Drug Administration (FDA) for the treatment of opioid-induced constipation (OIC) in non-ICU patients receiving scheduled moderate to high dose opioids for the treatment of chronic non-cancer pain. Naloxegol has a mechanism of action, efficacy, convenience of administration, and safety profile that make it an ideal candidate for use as a preventative medication for lower GI tract paralysis in critically ill adults receiving scheduled opioid therapy. The investigators propose a pilot study in which they will test the hypothesis that naloxegol (versus placebo) will reduce the time to the first spontaneous bowel movement (SBM) that an ICU patient has, that it will prevent lower GI tract paralysis in critically ill adults initiated on scheduled IV opioid therapy, and its use will not result in side effects that are concerning to doctors or patients. The investigators will randomize 36 critically ill ICU patients (18 in each arm) to receive naloxegol \[25mg or 12.5mg (in patients with a creatinine clearance ≤ 60ml/min)\] or placebo. This pilot study will provide valuable information to help guide future, larger studies evaluating the role of naloxegol in critically ill adults.

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 12

Inclusion Criteria

Age ≥ 18 years
Admitted to an ICU
Expected to require admission to an ICU for ≥ 48 hours
Intravenous opioid administration in the prior 24 hours of ≥ 100 mcg fentanyl equivalents

Exclusion Criteria

Scheduled use of an opioid ≥ 10 mg morphine equivalents per day in the week prior to ICU admission
History of constipation (≤ 2 SBM per week and current use of stool softener or laxative therapy) prior to ICU admission
Current scheduled use of a medication affecting gastric motility
Current use of a medication known to be a strong CYP3A4 inhibitor
History of a neurologic condition that may affect the permeability of the blood-brain barrier
Acute GI condition (e.g., clinical evidence of acute fecal impaction/complete obstruction, acute surgical abdomen, acute GI bleeding)
Condition affecting GI motility or function (e.g. inflammatory bowel disease requiring immunosuppressive therapy, symptomatic Clostridium difficile, active diverticular disease, surgery on the colon or abdomen within 60 days of ICU admission)
Current use of total parenteral nutrition
Administration of enteral nutrition through a jejunal tube
Severe hepatic dysfunction
Endstage renal disease defined as either i. calculated creatinine clearance ≤ 10ml/min or ii. Any current use of renal replacement therapy
Inability to enroll in study and initiate study medication within 48 hours of the patient begin first initiated on scheduled IV opioid therapy after ICU admission
Unreliable method for enteral, gastric and/or oral medication administration (e.g., no feeding tube, nasogastric tube is on suction)
Current or previous use of an opioid antagonist agent (e.g., naloxegol, methylnaltrexone) in the past 30 days
Pregnant or actively lactating females
Current participation in another interventional clinical study
Inability to obtain informed consent

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo Oral Tablet	Senna 217 Mg Oral Tablet	Intervention: Placebo tablet po (enteral) daily AND Docusate Sodium 100 mg Oral Capsule twice daily AND Study laxative protocol daily \[that may include Senna 217 mg Oral Tablet, Polyethylene Glycols (Miralax), Magnesium Citrate Oral Liquid Product (Citromag), Bisacodyl 10 mg Suppository (Dulcolax) and Methylnaltrexone (Relistor)\] until one of the following: 1. Adverse event potentially attributable to the study drug. 2. Use of Relistor. 3. Scheduled opioid therapy is stopped for ≥ 24 hours and participant has ≥ 1 SBM since enrollment. 4. The participant has been administered 10 days of study medication. 5. The participant is discharged from the ICU. 6. The participant requires the initiation of a strong CYP3A4 inhibitor medication. Other Name: AstraZeneca provided Movantik placebo
Naloxegol Oral Tablet	Senna 217 Mg Oral Tablet	Intervention: Naloxegol 25 mg (or 12.5 mg) tablet po (enteral) daily AND Docusate Sodium 100mg Oral Capsule twice daily AND Study laxative protocol daily \[that may include Senna 217 mg Oral Tablet, Polyethylene Glycols (Miralax), Magnesium Citrate Oral Liquid Product (Citromag), Bisacodyl 10 mg Suppository (Dulcolax) and Methylnaltrexone (Relistor)\] until one of the following: 1. Adverse event potentially attributable to the study drug. 2. Use of Relistor. 3. Scheduled opioid therapy is stopped for ≥ 24 hours and participant has ≥ 1 SBM since enrollment. 4. The participant has been administered 10 days of study medication. 5. The participant is discharged from the ICU. 6. The participant requires the initiation of a strong CYP3A4 inhibitor medication. Other Name: Movantik
Placebo Oral Tablet	Docusate Sodium 100 Mg oral capsule [Colace]	Intervention: Placebo tablet po (enteral) daily AND Docusate Sodium 100 mg Oral Capsule twice daily AND Study laxative protocol daily \[that may include Senna 217 mg Oral Tablet, Polyethylene Glycols (Miralax), Magnesium Citrate Oral Liquid Product (Citromag), Bisacodyl 10 mg Suppository (Dulcolax) and Methylnaltrexone (Relistor)\] until one of the following: 1. Adverse event potentially attributable to the study drug. 2. Use of Relistor. 3. Scheduled opioid therapy is stopped for ≥ 24 hours and participant has ≥ 1 SBM since enrollment. 4. The participant has been administered 10 days of study medication. 5. The participant is discharged from the ICU. 6. The participant requires the initiation of a strong CYP3A4 inhibitor medication. Other Name: AstraZeneca provided Movantik placebo
Naloxegol Oral Tablet	Magnesium Citrate Oral Liquid Product	Intervention: Naloxegol 25 mg (or 12.5 mg) tablet po (enteral) daily AND Docusate Sodium 100mg Oral Capsule twice daily AND Study laxative protocol daily \[that may include Senna 217 mg Oral Tablet, Polyethylene Glycols (Miralax), Magnesium Citrate Oral Liquid Product (Citromag), Bisacodyl 10 mg Suppository (Dulcolax) and Methylnaltrexone (Relistor)\] until one of the following: 1. Adverse event potentially attributable to the study drug. 2. Use of Relistor. 3. Scheduled opioid therapy is stopped for ≥ 24 hours and participant has ≥ 1 SBM since enrollment. 4. The participant has been administered 10 days of study medication. 5. The participant is discharged from the ICU. 6. The participant requires the initiation of a strong CYP3A4 inhibitor medication. Other Name: Movantik
Placebo Oral Tablet	Placebo Oral Tablet	Intervention: Placebo tablet po (enteral) daily AND Docusate Sodium 100 mg Oral Capsule twice daily AND Study laxative protocol daily \[that may include Senna 217 mg Oral Tablet, Polyethylene Glycols (Miralax), Magnesium Citrate Oral Liquid Product (Citromag), Bisacodyl 10 mg Suppository (Dulcolax) and Methylnaltrexone (Relistor)\] until one of the following: 1. Adverse event potentially attributable to the study drug. 2. Use of Relistor. 3. Scheduled opioid therapy is stopped for ≥ 24 hours and participant has ≥ 1 SBM since enrollment. 4. The participant has been administered 10 days of study medication. 5. The participant is discharged from the ICU. 6. The participant requires the initiation of a strong CYP3A4 inhibitor medication. Other Name: AstraZeneca provided Movantik placebo
Naloxegol Oral Tablet	Polyethylene Glycols	Intervention: Naloxegol 25 mg (or 12.5 mg) tablet po (enteral) daily AND Docusate Sodium 100mg Oral Capsule twice daily AND Study laxative protocol daily \[that may include Senna 217 mg Oral Tablet, Polyethylene Glycols (Miralax), Magnesium Citrate Oral Liquid Product (Citromag), Bisacodyl 10 mg Suppository (Dulcolax) and Methylnaltrexone (Relistor)\] until one of the following: 1. Adverse event potentially attributable to the study drug. 2. Use of Relistor. 3. Scheduled opioid therapy is stopped for ≥ 24 hours and participant has ≥ 1 SBM since enrollment. 4. The participant has been administered 10 days of study medication. 5. The participant is discharged from the ICU. 6. The participant requires the initiation of a strong CYP3A4 inhibitor medication. Other Name: Movantik
Naloxegol Oral Tablet	Naloxegol Oral Tablet	Intervention: Naloxegol 25 mg (or 12.5 mg) tablet po (enteral) daily AND Docusate Sodium 100mg Oral Capsule twice daily AND Study laxative protocol daily \[that may include Senna 217 mg Oral Tablet, Polyethylene Glycols (Miralax), Magnesium Citrate Oral Liquid Product (Citromag), Bisacodyl 10 mg Suppository (Dulcolax) and Methylnaltrexone (Relistor)\] until one of the following: 1. Adverse event potentially attributable to the study drug. 2. Use of Relistor. 3. Scheduled opioid therapy is stopped for ≥ 24 hours and participant has ≥ 1 SBM since enrollment. 4. The participant has been administered 10 days of study medication. 5. The participant is discharged from the ICU. 6. The participant requires the initiation of a strong CYP3A4 inhibitor medication. Other Name: Movantik
Naloxegol Oral Tablet	Bisacodyl 10 mg Suppository	Intervention: Naloxegol 25 mg (or 12.5 mg) tablet po (enteral) daily AND Docusate Sodium 100mg Oral Capsule twice daily AND Study laxative protocol daily \[that may include Senna 217 mg Oral Tablet, Polyethylene Glycols (Miralax), Magnesium Citrate Oral Liquid Product (Citromag), Bisacodyl 10 mg Suppository (Dulcolax) and Methylnaltrexone (Relistor)\] until one of the following: 1. Adverse event potentially attributable to the study drug. 2. Use of Relistor. 3. Scheduled opioid therapy is stopped for ≥ 24 hours and participant has ≥ 1 SBM since enrollment. 4. The participant has been administered 10 days of study medication. 5. The participant is discharged from the ICU. 6. The participant requires the initiation of a strong CYP3A4 inhibitor medication. Other Name: Movantik
Naloxegol Oral Tablet	Docusate Sodium 100 Mg oral capsule [Colace]	Intervention: Naloxegol 25 mg (or 12.5 mg) tablet po (enteral) daily AND Docusate Sodium 100mg Oral Capsule twice daily AND Study laxative protocol daily \[that may include Senna 217 mg Oral Tablet, Polyethylene Glycols (Miralax), Magnesium Citrate Oral Liquid Product (Citromag), Bisacodyl 10 mg Suppository (Dulcolax) and Methylnaltrexone (Relistor)\] until one of the following: 1. Adverse event potentially attributable to the study drug. 2. Use of Relistor. 3. Scheduled opioid therapy is stopped for ≥ 24 hours and participant has ≥ 1 SBM since enrollment. 4. The participant has been administered 10 days of study medication. 5. The participant is discharged from the ICU. 6. The participant requires the initiation of a strong CYP3A4 inhibitor medication. Other Name: Movantik
Placebo Oral Tablet	Polyethylene Glycols	Intervention: Placebo tablet po (enteral) daily AND Docusate Sodium 100 mg Oral Capsule twice daily AND Study laxative protocol daily \[that may include Senna 217 mg Oral Tablet, Polyethylene Glycols (Miralax), Magnesium Citrate Oral Liquid Product (Citromag), Bisacodyl 10 mg Suppository (Dulcolax) and Methylnaltrexone (Relistor)\] until one of the following: 1. Adverse event potentially attributable to the study drug. 2. Use of Relistor. 3. Scheduled opioid therapy is stopped for ≥ 24 hours and participant has ≥ 1 SBM since enrollment. 4. The participant has been administered 10 days of study medication. 5. The participant is discharged from the ICU. 6. The participant requires the initiation of a strong CYP3A4 inhibitor medication. Other Name: AstraZeneca provided Movantik placebo
Placebo Oral Tablet	Magnesium Citrate Oral Liquid Product	Intervention: Placebo tablet po (enteral) daily AND Docusate Sodium 100 mg Oral Capsule twice daily AND Study laxative protocol daily \[that may include Senna 217 mg Oral Tablet, Polyethylene Glycols (Miralax), Magnesium Citrate Oral Liquid Product (Citromag), Bisacodyl 10 mg Suppository (Dulcolax) and Methylnaltrexone (Relistor)\] until one of the following: 1. Adverse event potentially attributable to the study drug. 2. Use of Relistor. 3. Scheduled opioid therapy is stopped for ≥ 24 hours and participant has ≥ 1 SBM since enrollment. 4. The participant has been administered 10 days of study medication. 5. The participant is discharged from the ICU. 6. The participant requires the initiation of a strong CYP3A4 inhibitor medication. Other Name: AstraZeneca provided Movantik placebo
Placebo Oral Tablet	Bisacodyl 10 mg Suppository	Intervention: Placebo tablet po (enteral) daily AND Docusate Sodium 100 mg Oral Capsule twice daily AND Study laxative protocol daily \[that may include Senna 217 mg Oral Tablet, Polyethylene Glycols (Miralax), Magnesium Citrate Oral Liquid Product (Citromag), Bisacodyl 10 mg Suppository (Dulcolax) and Methylnaltrexone (Relistor)\] until one of the following: 1. Adverse event potentially attributable to the study drug. 2. Use of Relistor. 3. Scheduled opioid therapy is stopped for ≥ 24 hours and participant has ≥ 1 SBM since enrollment. 4. The participant has been administered 10 days of study medication. 5. The participant is discharged from the ICU. 6. The participant requires the initiation of a strong CYP3A4 inhibitor medication. Other Name: AstraZeneca provided Movantik placebo
Naloxegol Oral Tablet	Methylnaltrexone	Intervention: Naloxegol 25 mg (or 12.5 mg) tablet po (enteral) daily AND Docusate Sodium 100mg Oral Capsule twice daily AND Study laxative protocol daily \[that may include Senna 217 mg Oral Tablet, Polyethylene Glycols (Miralax), Magnesium Citrate Oral Liquid Product (Citromag), Bisacodyl 10 mg Suppository (Dulcolax) and Methylnaltrexone (Relistor)\] until one of the following: 1. Adverse event potentially attributable to the study drug. 2. Use of Relistor. 3. Scheduled opioid therapy is stopped for ≥ 24 hours and participant has ≥ 1 SBM since enrollment. 4. The participant has been administered 10 days of study medication. 5. The participant is discharged from the ICU. 6. The participant requires the initiation of a strong CYP3A4 inhibitor medication. Other Name: Movantik
Placebo Oral Tablet	Methylnaltrexone	Intervention: Placebo tablet po (enteral) daily AND Docusate Sodium 100 mg Oral Capsule twice daily AND Study laxative protocol daily \[that may include Senna 217 mg Oral Tablet, Polyethylene Glycols (Miralax), Magnesium Citrate Oral Liquid Product (Citromag), Bisacodyl 10 mg Suppository (Dulcolax) and Methylnaltrexone (Relistor)\] until one of the following: 1. Adverse event potentially attributable to the study drug. 2. Use of Relistor. 3. Scheduled opioid therapy is stopped for ≥ 24 hours and participant has ≥ 1 SBM since enrollment. 4. The participant has been administered 10 days of study medication. 5. The participant is discharged from the ICU. 6. The participant requires the initiation of a strong CYP3A4 inhibitor medication. Other Name: AstraZeneca provided Movantik placebo

Primary Outcome Measures

Name	Time	Method
Time to First Spontaneous Bowel Movement (SBM) Administration	First occurrence after study randomization during period of ICU admission or a maximum of 10 ICU days	Time to first spontaneous bowel movement during ICU admission after randomization

Secondary Outcome Measures

Name	Time	Method
Time to First Spontaneous Bowel Movement (SBM)	First occurrence after initiation of IV opioid therapy during period of ICU admission or a maximum of 10 ICU days	Time to first spontaneous bowel movement during the ICU admission after opioid initiation
Percentage of Daily Goal Reached for Enteral Nutrition Administration	From randomization to ICU discharge or a maximum of 10 ICU days	Enteral nutrition is assessed as daily volume in mL and the reported measure is the percentage of daily goal of enteral nutrition met.
Daily Maximal Pain Scale Score	From randomization to ICU discharge or a maximum of 10 ICU days	Based on the highest daily Visual Analogue Scale-10 or Clinical Pain Observation tool assessment. VAS-10 is Visual Analogue Scale which uses a nurse-administered 10 point rating scale. A measurement of 0-1 is minimal pain. A measurement of 10 is severe pain.
Abdominal Pressure Measurement	From randomization to ICU discharge (or removal of foley catheter) or a maximum of 10 ICU days	On days when the patient had a urinary catheter in place for clinical reasons, a bladder pressure transducer was inserted and abdominal pressure was measured. The average daily maximum pressure score for each group is reported.
ICU Days Without a SBM	During period of ICU admission or a maximum of 10 ICU days	Measured ICU days that subjects did not have a SBM
Number of Patients That Required Use of the Study Laxative Protocol	From randomization to ICU discharge or a maximum of 10 ICU days	A 4-step laxative protocol was initiated when there was no spontaneous bowel movement greater than or equal to 3 days time. Data collected on study laxative protocol included any use as well as the highest level needed.
Daily Fluid Balance	From randomization to ICU discharge or a maximum of 10 ICU days	Daily fluid balance measured in mL is the 24 hours ins and outs
Daily Maximal Sedation Assessment Scale (SAS) Score	From randomization to ICU discharge or a maximum of 10 ICU days	The Sedation Assessment Scale is rated 1 to 7. Score of 7 is dangerous agitation. Score of 1 is unarousable. Score of 2 is very sedated. The presence of coma is based on the every 4 hour sedation agitation score scale (SAS) assessment. A score of 1 or 2 any time during the day represents that a coma is present. A score of 3-7 represents a subject with no coma present. Results listed here is days without coma (SAS score of 3-7)
Occurrence of Lower GI Tract Paralysis Requiring GI/Surgical Consultation	From randomization to ICU discharge or a maximum of 10 ICU days	Number of patients with GI tract paralysis requiring Gastroenterology service or Surgical service consultation
Days Without Mechanical Ventilation Support for Duration of ICU Stay	From ICU admission to ICU discharge or a maximum of 10 ICU days	Measure is days without mechanical ventilation for duration of ICU stay as expressed as median and inter-Quartile Range
Time to First Episode of Diarrhea	Study drug initiation to first episode of diarrhea in hours.	The number of patients in each group with \> or equal to 1 episode of diarrhea after initiation of study drug. The time to first episode of diarrhea was measured in hours.
Occurrence of Lower GI Tract Paralysis (≥3 Days Without a SBM)	From randomization to ICU discharge or a maximum of 10 ICU days	Measurement is the number of subjects in each group having this occurrence of lower GI tract paralysis during time frame
Average Daily Opioid Requirement [in IV Fentanyl Equivalents (mcg Per Day)]	From randomization to ICU discharge or a maximum of 10 ICU days	Average daily opioid requirement is converted to IV fentanyl equivalent listed in mcg per day
Daily Difference in the Pre-dose and Post-dose Clinical Opioid Withdrawal Scale (COWS) Score	One hour before the daily study drug administration and 2 hours after the daily study drug administration	Patients were evaluated 1 hour before and 2 hours after the administration of each dose of study medication using the Clinical Opioid Withdrawal Scale (COWS). COWS is used to help determine the stage or severity of opiate withdrawal and assess the level of physical dependence on opioids. The COWS score ranges from 0-36+. A score of 0 is no active opioid withdrawal. A score of 5-12 is mild; 13-24 is moderate; 25-36 is moderately severe and more than 36 is severe opioid withdrawal.
Number of Patients With Loose and Unformed or Liquid SBM	From randomization to ICU discharge or a maximum of 10 ICU days	Consistency of SBM is characterized in one of 4 categories: hard and formed, soft but formed, loose and unformed, and liquid. The number listed in the results section is the number of patients who had either loose or liquid SBM (as opposed to hard or soft formed).
Daily Presence of Delirium Using the Intensive Care Delirium Screening Checklist (ICDSC)	From randomization to ICU discharge or a maximum of 10 ICU days	Measures as days without delirium with daily presence of delirium assessed using the Intensive Care Delirium Screening Checklist (ICDSC)